Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. [More]
Highland completes US$25 million offering of Class A Common Shares

Highland completes US$25 million offering of Class A Common Shares

Highland Therapeutics Inc., a pharmaceutical company, today announced it has completed a US$25 million offering of Class A Common Shares. The financing was led by a private equity partner that is committed to Highland's long-term success. [More]
Researchers develop DNA-based drug delivery system that targets cancer cells

Researchers develop DNA-based drug delivery system that targets cancer cells

Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale "cocoons" made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs. The work was done by researchers at North Carolina State University and the University of North Carolina at Chapel Hill. [More]
GenCell Biosystems acquired by Becton, Dickinson and Company

GenCell Biosystems acquired by Becton, Dickinson and Company

BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary technologies that address key biological analysis protocols – from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications. [More]
Impax executes definitive agreement to acquire Tower Holdings, Lineage Therapeutics

Impax executes definitive agreement to acquire Tower Holdings, Lineage Therapeutics

Impax Laboratories, Inc. today announced the execution of a definitive agreement under which Impax will acquire Tower Holdings, Inc., including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc. (together, the "Companies") for $700 million in cash, subject to certain customary purchase price adjustments. [More]
Gerresheimer Q3 revenues up 2.2% to EUR 323.9m

Gerresheimer Q3 revenues up 2.2% to EUR 323.9m

Gerresheimer AG again increased revenues in the third quarter of financial year 2014. [More]

Columbia Laboratories' subsidiary to unveil ROADMAP to Clinical Trials platform at CPhI/ICSE event

Columbia Laboratories, Inc., today announced that its subsidiary, Molecular Profiles Ltd., is set to unveil the ROADMAP to Clinical Trials platform at the annual CPhI/ICSE Worldwide event in Paris next week, which aims to support companies with the rapid development of both standard and complex drug products. [More]
FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. [More]
International organizations join forces to develop inhaled form of oxytocin for postpartum hemorrhage

International organizations join forces to develop inhaled form of oxytocin for postpartum hemorrhage

An international group of public and private organizations is collaborating to accelerate development of an innovative heat-stable and low-cost inhaled form of oxytocin to manage postpartum hemorrhage in resource-poor settings. [More]
Enable Injections named winner of 'Buzz of BIO Investor Forum' contest

Enable Injections named winner of 'Buzz of BIO Investor Forum' contest

Enable Injections, developer of a novel wearable 'bolus injector' that may soon make it easy and nearly painless for patients to self-inject large-dose biologic drugs in the comfort of their homes, has been named winner of the 'Buzz of BIO Investor Forum' contest recognizing highly innovative companies in the biotech sector. [More]
Sanovas announces commercialization of MicroCam System via Healthmark Industries

Sanovas announces commercialization of MicroCam System via Healthmark Industries

Sanovas Inc., a Life Science company accelerating the development and commercialization of next-generation micro-invasive diagnostics, devices and drug delivery technologies, announced today that its MicroCam Inc. subsidiary has commenced commercialization of the MicroCam System via its OEM partnership with Healthmark Industries, which is launching its new product—Flexible Inspection Scope—this week. [More]
New approach to imaging metastatic tumors

New approach to imaging metastatic tumors

Bioluminescence, nanoparticles, gene manipulation - these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors. [More]

Fast release drug delivery capsule launched by Medimetrics

Medtech innovator Medimetrics continues its expansion into the global medical devices sector with official recognition of its full design and product development capabilities and the launch of a new, fast release, drug delivery capsule. [More]
Miriam Hospital receives grant from NIH to prevent spread of sexually transmitted HIV in women

Miriam Hospital receives grant from NIH to prevent spread of sexually transmitted HIV in women

The Miriam Hospital is part of a research collaboration that has received a $20 million grant from the National Institutes of Health (NIH) to develop an intravaginal ring (IVR) that can deliver powerful antiretroviral (ARV) drugs to prevent the spread of sexually transmitted HIV in women. [More]
Non-invasive delivery of drugs for effective pain relief

Non-invasive delivery of drugs for effective pain relief

Individuals who are squeamish about injections or are looking for a way to let collagen penetrate deeper into the skin may soon have a solution that is faster, more effective and painless. [More]
Three Clemson startup companies receive $25,000 in seed money from USAP

Three Clemson startup companies receive $25,000 in seed money from USAP

Clemson University Research Foundation (CURF) announced that three Clemson startup companies have each received $25,000 in seed money from the University Sponsored Application Program (USAP) offered by SC Launch. [More]

Professor Bill Charman awarded FIP Lifetime Achievement Award in Pharmaceutical Sciences

The International Pharmaceutical Federation has honoured a prominent Monash scientist and Dean for his outstanding contribution to pharmaceutical sciences. [More]
New vaccine in bid to move away from needles and syringes to skin delivery procedures

New vaccine in bid to move away from needles and syringes to skin delivery procedures

Drug delivery technologies that improve access and overall efficacy are becoming an essential part of the entire drug development process. [More]
Semi-soft vaginal suppository provides drug-delivery vehicle to prevent spread of HIV

Semi-soft vaginal suppository provides drug-delivery vehicle to prevent spread of HIV

A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences. [More]
iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]